GlobeNewswire Inc | Jan 5, 2022 07:30AM EST

January 05, 2022

WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present during the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET.

A live webcast will be available in the Investors & Media section of Dynes website at https://investors.dyne-tx.com/news-and-events/events-and-presentationsand a replay will be accessible for 30 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases.With its proprietary FORCE platform, Dyne is developing modern oligonucleotide therapeutics that are designed toovercome limitations in delivery to muscle tissue seen with other approaches.Dyne has a broad portfolio of therapeutic candidates for serious muscle diseases, including myotonicdystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us onTwitter,LinkedInandFacebook.

Contact:

Dyne TherapeuticsAmy Reillyareilly@dyne-tx.com857-341-1203